Evidence map›Paper›PMID 29795754›Full record

ArticleACS medicinal chemistry letters2018

Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.

Irene de Miguel, Josune Orbe, Juan A Sánchez-Arias, José A Rodríguez, Agustina Salicio, Obdulia Rabal, Miriam Belzunce, Elena Sáez, Musheng Xu, Wei Wu and 4 more

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Irene de MiguelSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Josune OrbeSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Juan A Sánchez-AriasSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
José A RodríguezSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Agustina SalicioSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Obdulia RabalSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Miriam BelzunceSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Elena SáezSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Musheng XuWuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, Fourth Avenue, Tianjin 300456, P. R. China.
Wei WuWuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, Fourth Avenue, Tianjin 300456, P. R. China.
Haizhong TanWuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, Fourth Avenue, Tianjin 300456, P. R. China.
Hongyu MaWuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, Fourth Avenue, Tianjin 300456, P. R. China.
José A PáramoSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Julen OyarzabalSmall Molecule Discovery Platform, Molecular Therapeutics Program, and Atherothrombosis Research Laboratory, Program of Cardiovascular Diseases, Center for Applied Medical Research (CIMA), Universidad de Navarra, Pamplona, Spain.
Universidad de Navarra · ESInstituto de Salud Carlos III · ESWuXi AppTec (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In an effort to find novel chemical series as antifibrinolytic agents, we explore α-phenylsulfonyl-α-spiropiperidines bearing different zinc-binding groups (ZBGs) to target those metalloproteinases involved in the fibrinolytic process: MMP3 and MMP10. Surprisingly, all these new chemical series were inactive against these metalloproteinases; however, several new molecules retained the antifibrinolytic activity in a phenotypic functional assay using thromboelastometry and human whole blood. Further optimization led to compound

Identifiers

PMID29795754
PMCPMC5949812
OpenAlexW2802355367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.